CD44 Is a Cytotoxic Triggering Molecule on Human Polymorphonuclear Cells

Journal of Immunology

Volumn 157, Issue 10, 1996, Pages 4657-4663

  Pericle, Federica ^a   Sconocchia, Giuseppe ^a   Titus, Julie A ^a   Segal, David M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG EFFECT; HUMAN; IMMUNOLOGY; MOUSE; NEUTROPHIL;

ANIMALS; ANTIGENS, CD44; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; HYALURONIC ACID; MICE; NEUTROPHILS; TUMOR CELLS, CULTURED;

EID: 0030588697     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Segal, D. M., C. R. Jost, and A. J. T. George. 1993. Targeted cellular cytotoxicity. In Cytotoxic Cells: Generation, Recognition, Effector Functions, Methods. M. V. Sitkovsky and P. A. Henkart, eds. Springer-Verlag, New York, p. 96.
2. Karpovsky, B., J. A. Titus, D. A. Stephany, and D. M. Segal. 1984. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Exp. Med. 160:1686.
3. Perez, P., R. W. Hoffman, J. A. Titus, and D. M. Segal. 1986. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J. Exp. Med. 163:166.
4. Segal, D. M., T. Bakacs, C. R. Jost, I. Kurucz, G. Sconocchia, and J. A. Titus. 1995. T cell-targeted cytotoxicity. In Bispecific Antibodies. M. W. Fanger, ed. R. G. Landes Co., Austin, p. 27.
5. Wallace, P. K., F. H. Valone, and M. W. Fanget. 1995. Myeloid cell-targeted cytotoxicity of tumor cells. In Bispecific Antibodies. M. W. Fanger, ed. R. G. Landes Co., Austin, p. 43.
6. Siliciano, R. F., J. C. Pratt, R. E. Schmidt, J. Ritz, and E. L. Reinherz. 1985. Activation of cytotoxic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature 317:428.
7. + T lymphocytes via CD2 requires triggering via the T11.1 epitope only. J. Immunol. 142:1797.
8. 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol. 147:60.
9. MEL-14. Proc. Natl. Acad. Sci. USA 88:7877.
10. Galandrini, R., N. Albi, G. Tripodi, D. Zarcone, A. Terenzi, A. Moretta, C. E. Grossi, and A. Velardi. 1993. Antibodies to CD44 trigger effector functions of human T cell clones. J. Immunol. 150:4225.
11. Moretta, A., A. Poggi, D. Pende, G. Tripodi, A. M. Orengo, N. Pella, R. Augugliaro, C. Bottino, E. Ciccone, and L. Moretta. 1991. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor α/β. J. Exp. Med. 174:1393.
12. Sconocchia, G., J. A. Titus, and D. M. Segal. 1994. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells. J. Immunol. 153:5473.
13. Haynes, B. F., M. J. Telen, L. P. Hale, and S. M. Denning. 1989. CD44-A molecule involved in leukocyte adherence and T-cell activation. Immunol. Today 10:423.
14. Lesley, J., R. Hyman, and P. W. Kincade. 1993. CD44 and its interaction with extracellular matrix. Adv. Immunol. 54:271.
15. Aruffo, A., I. Stamenkovic, M. Melnick, C. B. Underhill, and B. Seed. 1990. CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303.
16. Weber, G. F., S. Ashkar, M. J. Glimcher, and H. Cantor. 1996. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509.
17. Valerius, T., R. Repp, T. P. de Wit, S. Berthold, E. Platzer, J. R. Kalden, M. Gramatzki, and J. G. Van de Winkel. 1993. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 82:931.
18. Michon, J., S. Moutel, J. Barbet, J. L. Romet-Lemonne, Y. M. Deo, W. H. Fridman, and J. L. Teillaud. 1995. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody. Blood 86: 1124.
19. Huizinga, T. W. J., C. E. van der Shoot, C. Jost, R. Klaassen, M. Kleijr, A. E. G. von dem Borne, D. Roos, and P. A. T. Tetteroo. 1988. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 333:667.
20. Selvaraj, P., W. F. Rosse, R. Silber, and T. A. Springer. 1988. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 333:565.
21. Lanier, L. L., J. J. Ruitenberg, and J. H. Phillips. 1988. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J. Immunol. 141:3478.
22. van Kessel, K. P., and J. Verhoef. 1990. A view to a kill: cytotoxic mechanisms of human polymorphonuclear leukocytes compared with monocytes and natural killer cells. Pathobiology 58:249.
23. Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853.
24. Pericle, F., R. A. Kirken, P. K. Epling-Burnette, D. K. Blanchard, and J. Y. Djeu. 1996. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int. J. Cancer 66:367.
25. Nanni, P., C. de Giovanni, P. L. Lollini, G. Nicoletti, and G. Prodi. 1983. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1:373.
26. Titus, J. A., P. Perez, A. Kaubisch, M. A. Garrido, and D. M. Segal. 1987. Human K/NK cells targeted with heterocrosslinked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. 139:3153.
27. Mosmann, T. R. 1983. A rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J. Immunol. Methods 65:55.
28. Tada, H., O. Shiho, K. Kuroshima, M. Koyama, and K. Tsukamoto. 1986. An improved colorimetric assay for interleukin 2. J. Immunol. Methods 93:157.
29. Lisanti, M. P., and M. Sargiacomo. 1995. Biotinylation and analysis of membrane-bound and soluble proteins. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley and Sons, New York. p. 8.16.1.
30. Henkart, P. A. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343.
31. 2 pool generated by human neutrophils. J. Biol. Chem. 259: 399.
32. Schraufstatter, I. U., K. Browne, A. Harris, P. A. Hyslop, J. H. Jackson, O. Quehenberger, and C. G. Cochrane. 1990. Mechanisms of hypochlorite injury of target cells. J. Clin. Invest. 85:554.
33. Lesley, J., N. English, A. Perschl, J. Gregoroff, and R. Hyman. 1995. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J. Exp. Med. 182:431.
34. Perschl, A., J. Lesley, N. English, I. Trowbridge, and R. Hyman. 1995. Role of CD44 cytoplasmic domain in hyaluronan binding. Eur. J. Immunol. 25:495.
35. Liao, H.-X., M. C. Levesque, K. Patton, B. Bergamo, D. Jones, M. A. Moody, M. J. Telen, and B. F. Haynes. 1993. Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies. J. Immunol. 151:6490.
36. Puré, E., R. L. Camp, D. Peritt, R. A. Panettieri, Jr., A. L. Lazaar, and S. Nayak. 1995. Defective phosphorylation and hyaluronate binding of CD44 with point mutations in the cytoplasmic domain. J. Exp. Med. 181:55.
37. Uff, C. R., S. J. Neame, and C. M. Isacke. 1995. Hyaluronan binding by CD44 is regulated by a phosphorylation-independent mechanism. Eur. J. Immunol. 25: 1883.
38. Lesley, J., Q. He, K. Miyake, A. Hamann, R. Hyman, and P. W. Kincade. 1992. Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J. Exp. Med. 175:257.
39. Katoh, S., Z. Zheng, K. Oritani, T. Shimozato, and P. W. Kincade. 1995. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med. 182:419.
40. Bennett, K. L., B. Modrell, B. Greenfield, A. Bartolazzi, I. Stamenkovic, R. Peach, D. G. Jackson, F. Spring, and A. Aruffo. 1995. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol. 131:1623.
41. Bartolazzi, A., A. Nocks, A. Aruffo, F. Spring, and I. Stamenkovic. 1996. Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J. Cell Biol. 132:1199.
42. Hathcock, K. S., H. Hirano, S. Murakami, and R. J. Hodes. 1993. CD44 expression on activated B cells: differential capacity for CD44-dependent binding to hyaluronic acid. J. Immunol. 151:6712.
43. Rot, A. 1992. Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol. Today 13:291.
44. Reading, C. L., and J. T. Hutchins. 1985. Carbohydrate structure in tumor immunity. Cancer Metastasis Rev. 4:221.